Table of Contents PART 01: Executive summary PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 06: Market segmentation by indication • Influenza A • Influenza B • Influenza C PART 07: Market segmentation by product • Immunodiagnostics • Market size and forecast • POCT • Market size and forecast • Molecular diagnostics • Market size and forecast PART 08: Market segmentation by end-users • Hospitals and diagnostic laboratories • Academic and research institutes • Home care PART 09: Geographical segmentation • Influenza diagnostics market in Americas • Influenza diagnostics market in EMEA • Influenza diagnostics market in APAC PART 10: Market drivers • Increasing demand for POC diagnostics • Growing demand for automation and system integration • Climatic condition-dependent influenza diagnostic testing PART 11: Impact of drivers PART 12: Market challenges • Challenges related to laboratory diagnosis for emerging influenza viruses • Ethical issues related to pandemic influenza • Strained laboratory budgets and lowering reimbursement affecting instrument sales PART 13: Impact of drivers and challenges PART 14: Market trends • Potential opportunities for POL • Leasing of influenza diagnostics instruments • Technological advancements in detection of influenza diseases PART 15: Vendor landscape PART 16: Key vendor analysis • Alere • Becton Dickinson • bioMerieux • Quidel • Key companies to watch • Other prominent vendors PART 17: Appendix • List of abbreviations   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Global influenza diagnostics market overview Exhibit 03: Global influenza diagnostics market ($ billions) Exhibit 04: Market analysis of influenza diagnostics market 2016 Exhibit 05: cobas Liat Influenza A/B: Features and specifications Exhibit 06: Five forces analysis Exhibit 07: Types of human influenza viruses Exhibit 08: Influenza A products Exhibit 09: Influenza A and B products Exhibit 10: Global influenza immunodiagnostics market 2016-2021 ($ millions) Exhibit 11: Immunodiagnostics metrics analysis Exhibit 12: Global influenza POCT market 2016-2021 ($ billions) Exhibit 13: Pros and cons of POCT testing Exhibit 14: POCT metrics analysis Exhibit 15: Global influenza molecular diagnostics market 2016-2021 ($ millions) Exhibit 16: Molecular diagnostics metrics analysis Exhibit 17: Global influenza diagnostics market segmentation by end-users 2015 Exhibit 18: Various types of reference measurement services Exhibit 19: Global clinical reference laboratory services market share by service provider 2015 and 2020 (% share) Exhibit 20: Global influenza diagnostics market by geography 2016-2021 Exhibit 21: Influenza diagnostics market in Americas overview Exhibit 22: Influenza diagnostics market in Americas ($ billions) Exhibit 23: Influenza diagnostics market in EMEA overview Exhibit 24: Influenza diagnostics market in EMEA ($ millions) Exhibit 25: Influenza diagnostics market in APAC overview Exhibit 26: Influenza diagnostics market in APAC ($ millions) Exhibit 27: Advantages of POC diagnostics Exhibit 28: CLIA-waived influenza diagnostics products Exhibit 29: Typical seasonal patterns of influenza activity in selected countries Exhibit 30: Impact of drivers Exhibit 31: Impact of drivers and challenges Exhibit 32: Leasing of influenza diagnostics instruments Exhibit 33: Competitive structure analysis of global influenza diagnostics market 2016 Exhibit 34: Global influenza diagnostics market: Competitive landscape Exhibit 35: Alere: Strength assessment Exhibit 36: Alere: Strategy assessment Exhibit 37: Alere: Opportunity assessment Exhibit 38: Becton Dickinson: Strength assessment Exhibit 39: Becton Dickinson: Strategy assessment Exhibit 40: Becton Dickinson: Opportunity assessment Exhibit 41: bioMerieux: Strength assessment Exhibit 42: bioMerieux: Strategy assessment Exhibit 43: bioMerieux: Opportunity assessment Exhibit 44: Quidel: Strength assessment Exhibit 45: Quidel: Strategy assessment Exhibit 46: Quidel: Opportunity assessment

Alere, Becton Dickinson, bioMerieux, Quidel, Autoimmune Technologies, Biocartis, EKF Diagnostics, Grifols, Meridian Bioscience, Response Biomedical, SA Scientific, and Sekisui Medical.